AEHR vs. TXG, TRNS, EYPT, ALNT, LAB, CTKB, QSI, QTRX, SENS, and MASS
Should you be buying Aehr Test Systems stock or one of its competitors? The main competitors of Aehr Test Systems include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Allient (ALNT), Standard BioTools (LAB), Cytek Biosciences (CTKB), Quantum-Si (QSI), Quanterix (QTRX), Senseonics (SENS), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Aehr Test Systems vs. Its Competitors
Aehr Test Systems (NASDAQ:AEHR) and 10x Genomics (NASDAQ:TXG) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.
In the previous week, 10x Genomics had 1 more articles in the media than Aehr Test Systems. MarketBeat recorded 7 mentions for 10x Genomics and 6 mentions for Aehr Test Systems. 10x Genomics' average media sentiment score of 0.82 beat Aehr Test Systems' score of 0.13 indicating that 10x Genomics is being referred to more favorably in the news media.
Aehr Test Systems has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500.
Aehr Test Systems has a net margin of 37.17% compared to 10x Genomics' net margin of -25.14%. Aehr Test Systems' return on equity of 21.15% beat 10x Genomics' return on equity.
Aehr Test Systems has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Aehr Test Systems, indicating that it is currently the more affordable of the two stocks.
69.7% of Aehr Test Systems shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 6.2% of Aehr Test Systems shares are held by insiders. Comparatively, 9.4% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Aehr Test Systems presently has a consensus price target of $25.00, suggesting a potential upside of 61.19%. 10x Genomics has a consensus price target of $14.96, suggesting a potential upside of 15.00%. Given Aehr Test Systems' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aehr Test Systems is more favorable than 10x Genomics.
Summary
Aehr Test Systems beats 10x Genomics on 10 of the 16 factors compared between the two stocks.
Get Aehr Test Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for AEHR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AEHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aehr Test Systems Competitors List
Related Companies and Tools
This page (NASDAQ:AEHR) was last updated on 7/4/2025 by MarketBeat.com Staff
